2008
DOI: 10.1080/13813450801969715
|View full text |Cite
|
Sign up to set email alerts
|

The role of insulin receptors and IGF-I receptors in cancer and other diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
214
0
9

Year Published

2009
2009
2018
2018

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 356 publications
(226 citation statements)
references
References 165 publications
3
214
0
9
Order By: Relevance
“…As we found a close relationship between rRNA synthesis upregulation and the reduction of p53 function, we believe that a reduced tumour suppressor activity of p53 might contribute to increasing the risk of cancer development in the above mentioned tissue lesions, in which a stimulation of rRNA synthesis occurred as a consequence of the increased cell proliferation rate (Montanaro et al, 2008). Furthermore, a reduced p53 activity consequent to rRNA synthesis upregulation might explain the increased risk of cancer onset in people with obesity, insulin resistance and type II diabetes, all conditions that are characterised by a hyperinsulinemic status with activation of the insulin and IGF-1 pathways (Renehan et al, 2006(Renehan et al, , 2008Frasca et al, 2008;Cannata et al, 2010), and also might be responsible for the worse evolution of cancer in patients with the above mentioned metabolic features, by reducing the efficacy of the anti-tumour therapies that activate p53 (Renehan et al, 2006(Renehan et al, , 2008Frasca et al, 2008;Cannata et al, 2010).…”
Section: Discussionmentioning
confidence: 99%
“…As we found a close relationship between rRNA synthesis upregulation and the reduction of p53 function, we believe that a reduced tumour suppressor activity of p53 might contribute to increasing the risk of cancer development in the above mentioned tissue lesions, in which a stimulation of rRNA synthesis occurred as a consequence of the increased cell proliferation rate (Montanaro et al, 2008). Furthermore, a reduced p53 activity consequent to rRNA synthesis upregulation might explain the increased risk of cancer onset in people with obesity, insulin resistance and type II diabetes, all conditions that are characterised by a hyperinsulinemic status with activation of the insulin and IGF-1 pathways (Renehan et al, 2006(Renehan et al, , 2008Frasca et al, 2008;Cannata et al, 2010), and also might be responsible for the worse evolution of cancer in patients with the above mentioned metabolic features, by reducing the efficacy of the anti-tumour therapies that activate p53 (Renehan et al, 2006(Renehan et al, , 2008Frasca et al, 2008;Cannata et al, 2010).…”
Section: Discussionmentioning
confidence: 99%
“…The IGF system (IGF-I, IGF-II, IGF-binding protein, and IGF-IR) performs an important role in the growth of various cancer cells, including colon cancer cells (Frasca et al, 2008;Jung et al, 2008). Luteolin, dose-dependently reduced the IGF-2 secretion of HT-29 cells.…”
Section: Luteolin Effects On Igf-1mentioning
confidence: 99%
“…Linked to their proliferative, differentiation and apoptotic properties, both GH and insulin-like growth factor 1 (IGF1) have been identified as risk factors for certain malignancies (1)(2)(3)(4)(5), even in the pediatric age group and young adults (6)(7)(8). There is also evidence that most tumors and transformed cells display increased IGF1 receptor (IGF-1R) concentration and high IGF1R mRNA, causing enhanced IGF1 binding (9,10), leading to the axiom that overexpression of IGF1R is a pre-requirement for acquisition or progress of malignant tumors (11).…”
Section: Introductionmentioning
confidence: 99%